Search PubMed⌕ Search

Biomedical subjects

R L Ryall

Publications and source records attributed to R L Ryall.

At least 55 records · Page 3Linked to original sources

Urate and calcium stones--picking up a drop of mercury with one's fingers?

The evidence invariably cited to support the suspicion that urinary urate is a predisposing factor in calcium oxalate (CaOx) stone formation is critically reviewed. Analysis of the relevant literature shows that speculation is based on the clinical impression that CaOx stone-formers appear to excrete more urate than do normal subjects, and that allopurinol reduces the rate of CaOx stone recurrences. On balance, this is sufficient to suggest that a high urinary excretion of urate promotes CaOx stone formation. However, in the past, evidence to disclose the mechanism by which urate could exert this effect has been largely shrouded in confusion and controversy. The evidence for two theories that have dominated thinking in this area are reviewed and new findings are reported that indicate that neither can account for the purported effect of urate. It is concluded that dissolved urate in urine, at normal physiological pH values, directly provokes CaOx crystal nucleation by the phenomenon of salting-out. The possibility that urate promotes CaOx stone formation is further strengthened by its ability to increase significantly the amount of CaOx precipitated from solution and to cause the aggregation of individual crystals into large clusters. Future avenues of investigation that should assist in the formulation of diagnostic and therapeutic guidelines are presented.

Allopurinol↗

Inhibition by sodium-potassium citrate (CG-120) of calcium oxalate crystal growth on to kidney stone fragments obtained from extracorporeal shock wave lithotripsy.

Retention of fragments within the kidney after extracorporeal shock wave lithotripsy (ESWL) continues to be a major shortcoming of this form of stone treatment. The aim of this study was to evaluate the ability of sodium-potassium citrate to inhibit calcium oxalate crystal nucleation and growth on to stone fragments remaining after ESWL. The continuous flow crystallisation technique was adapted to induce calcium oxalate crystal nucleation and growth on to the surface of fragmented kidney stones and the inhibitory effect of sodium-potassium citrate was assessed by scanning electron microscopy and by determining the relative increase in crystalline mass at final concentrations of 0, 2, 4, 6, 8, 10 mmol/l. Sodium-potassium citrate significantly inhibited the deposition of new crystalline calcium oxalate in a dose-dependent manner above 2 mmol/l; these findings were confirmed by scanning electron microscopy. It was concluded that sodium-potassium citrate may provide an effective means of preventing the formation of new kidney stones by the deposition of calcium oxalate on to residual stone fragments resulting from ESWL and that the technique used is an efficient means of testing the efficacy of therapeutic agents to prevent stone recurrence in patients treated with ESWL.

Calcium Oxalate↗

Inclusion of proteins into calcium oxalate crystals precipitated from human urine: a highly selective phenomenon.

The abundance of protein in the matrix of calcium oxalate uroliths has fueled speculation regarding its role in stone genesis. In this study, we wanted to characterize the composition of the proteins associated with early stages of calcium oxalate crystallization in urine. Calcium oxalate crystallization was induced in urine from healthy men and women by the addition of an oxalate load. The crystals were harvested and demineralized, and the proteins remaining were separated and characterized by polyacrylamide gel electrophoresis and Western blotting. Most urinary proteins were not detected in the crystals or were present in only small quantities. The most abundant urinary macromolecule, Tamm-Horsfall glycoprotein, was notably absent from the crystal extracts. The predominant protein associated with the crystals, a previously unknown urinary constituent that we call crystal matrix protein (CMP; molecular mass, 30,000 Da), was more prevalent in the crystals derived from female urine. We conclude that most urinary proteins play no direct role in calcium oxalate crystal formation. However, the protein CMP exhibits a remarkable affinity for calcium oxalate crystals and may be important in stone pathogenesis.

Blotting, Western↗

Does Tamm-Horsfall mucoprotein inhibit or promote calcium oxalate crystallization in human urine?

Using two different experimental techniques, Tamm-Horsfall mucoprotein (THM) has been reported both to inhibit and to promote calcium oxalate (CaOx) crystallization in ultrafiltered human urine. In this study, these two techniques were used to compare the effects of THM on CaOx crystallization in the same ultrafiltered urine samples. Urine was collected from 10 healthy men and ultrafiltered (10,000 Da). Each sample was divided and to one half was added sufficient human THM to give a final concentration of 35 mg/L. CaOx crystallization was induced in the samples by addition of an oxalate load and by evaporation. Using the evaporation technique THM significantly increased the deposition of CaOx determined as 14C-oxalate, from 9,772 cpm to 43,652 cpm (P less than 0.01). Using the oxalate load method THM had no effect on the metastable limits of the urine with respect to CaOx, and significantly increased the volume of particulate material deposited from 26,000 to 39,995 microns 3/microliters - an increase of 54%. This increase was reduced to 21% when values were corrected for the volume of THM particles recorded in control samples to which no oxalate load was added. Using 14C-oxalate, it was shown that this increase in volume could not be attributed to an enhanced deposition of crystalline CaOx, but was probably the result of an increased polymerization of THM in the presence of CaOx crystals. Despite this, the average size of the particles precipitated in the presence of THM (6.5 microns) was significantly (P less than 0.01) less than that observed in the absence of THM (12.1 microns). It was concluded that the effect of THM on CaOx crystallization in urine depends upon the methodology used to assess it and that promotion would only be expected in vivo in cases of extreme dehydration. Under usual physiological conditions THM would be expected to inhibit CaOx crystal aggregation and to have little effect, if any, on the amount of crystalline material deposited.

Adult↗

The effect of decreasing the concentration of urinary urate on the crystallization of calcium oxalate in undiluted human urine.

The effect of lowering the urate concentration, using uricase immobilized on to nylon tubing, on the nucleation, growth and aggregation of calcium oxalate crystals in undiluted human urine was examined. The median urate concentration was significantly (p less than 0.01) reduced from 2.8 to 0.55 mmol/l., but this had no reproducible effect on the metastable limits, the volume of crystalline calcium oxalate deposited and the size of the crystals and aggregates produced from the 10 urine samples examined. It was concluded that further studies aimed at testing the effects of a raised urinary urate concentration on the crystallization of calcium oxalate should be made a matter of high priority.

Calcium Oxalate↗

Effect of urate on calcium oxalate crystallization in human urine: evidence for a promotory role of hyperuricosuria in urolithiasis.

1. The effect of hyperuricosuria, simulated by increasing the concentration of dissolved urate, on the crystallization of calcium oxalate in human urine was examined. 2. Twenty urine samples were studied. Ten of these, designated type A, spontaneously precipitated calcium oxalate dihydrate crystals upon the addition of a solution of sodium urate solution which raised the median urate concentration from 3.1 to 7.0 mmol/l. 3. Adding dissolved urate to the remaining type B samples raised the median urate concentration from 2.2 to 6.2 mmol/l, but did not cause the precipitation of calcium oxalate. This was induced in these samples by the addition of a standard load of oxalate above an empirically determined metastable limit. 4. In the type B urine samples, the addition of urate decreased the median metastable limit from 125 to 66 mumol of oxalate, trebled the median volume of crystalline calcium oxalate deposited from 35,000 to 105,000 microns3/microliters and significantly increased the overall size of the particles precipitated. Calcium oxalate monohydrate was exclusively precipitated, and the individual crystals deposited in the presence of urate were markedly smaller, more numerous, and more highly aggregated than those produced in its absence. 5. These results constitute the most convincing evidence yet obtained that hyperuricosuria may be a powerful promoter of calcium oxalate stone formation.

Adult↗

Macromolecules inhibit calcium oxalate crystal growth and aggregation in whole human urine.

Removal of macromolecules with Mr greater than 10,000 had no discernible effect on the detectable nucleation of calcium oxalate crystals from undiluted human urine, but promoted the deposition of crystalline material and markedly increased the degree of aggregation of the precipitated crystals. Calcium oxalate crystals and crystal aggregates precipitated from ultrafiltered urine were, on average, 68% larger than those deposited from whole urine. These findings suggest that urinary macromolecules play a key role in preventing calcium oxalate kidney stone disease by inhibiting the formation of large crystal aggregates and thereby reducing the probability of particle retention in the kidney tubules.

Calcium Oxalate↗

The effect of serum on the crystallization of calcium oxalate in whole human urine: inhibition disguised as apparent promotion.

The effect of serum on calcium oxalate crystallization was studied in whole human urine. At concentrations between 0.005% to 0.10% (v/v), serum had no effect on the metastable limit of urine as detected by the Coulter Counter. However, serum caused a marked increase in the number and volume of calcium oxalate crystals deposited in response to an oxalate load. That this increase in volume reflected true deposition of calcium oxalate was confirmed by determining calcium concentration and by including control urines containing added serum but no exogenous oxalate. Analysis of particle size distributions showed that the crystals deposited in the presence of serum were smaller than those occurring in the control. Since serum did not affect the limit of metastability, the enhancement of crystal volume is unlikely to be a result of heterogeneous nucleation. We hypothesize that the apparent promotion effect of serum is due to its inhibition of crystal aggregation which increases the crystal surface area available for calcium oxalate deposition.

Blood↗

Urinary risk factors in calcium oxalate stone disease: comparison of men and women.

The daily excretion of calcium, oxalate, uric acid and glycosaminoglycans, the 24-h urinary pH and volume, and the inhibitory effects of the urines on calcium oxalate crystal growth and aggregation, were measured in 44 normal women, 41 normal men, 32 female stone formers and 63 male stone formers. No significant differences could be found between the normal men and women, the male and female stone formers, or between the patients and their normal controls with regard to the excretion of oxalate and glycosaminoglycans, and the urinary pH. The normal women exhibited significantly lower urinary volumes and excreted less calcium per day than did the other subject groups. The excretion of calcium by the female stone formers was indistinguishable from that of both groups of men. The male and female stone formers did not differ from their corresponding control groups with regard to the excretion of urate, but both groups of male subjects had significantly higher daily urate excretions than did either female category. This was attributed to the greater body weights of the men. There were no discernible differences between any of the subject groups with regard to the inhibitory effects of their urines on calcium oxalate crystal growth, but urines from both groups of female subjects demonstrated a significantly greater inhibitory influence on crystal aggregation than did those of the men. It would appear that the relatively low incidence of uninfected calcium oxalate urolithiasis in women compared with men may be attributable to (a) a lower daily calcium excretion and (b) a higher inhibitory activity of their urines towards crystal aggregation.

Adult↗

The influence of serum and serum proteins on calcium oxalate crystal growth and aggregation.

The effects of serum, albumin, alpha-globulin, and a mixture of alpha- and beta-globulin on the growth and aggregation of calcium oxalate crystals were measured in a standard seeded crystallisation system. At concentrations below 0.01% blood, which corresponded to microscopic haematuria, all were potent inhibitors of crystal aggregation whilst only having a minor effect on crystal growth. It was found that albumin, alpha-globulin and beta-globulin can account for the total inhibitory effect of serum on crystal growth and crystal aggregation.

Alpha-Globulins↗

Inhibitory activity of whole urine: a comparison of urines from stone formers and healthy subjects.

The inhibitory activity of whole urines from 32 healthy subjects and 50 calcium oxalate renal stone formers was assessed in terms of their ability to withstand increasing quantities of oxalate before undergoing spontaneous nucleation of calcium oxalate, and their response to a standard 30-mumol challenge of oxalate above their measured metastable limits. The concentrations of calcium (p less than 0.05), oxalate (p less than 0.05), urate (p less than 0.01) and glycosaminoglycans (p less than 0.005) were significantly lower in the stone formers than in the controls and were associated with a significantly higher 24-h urinary volume (p less than 0.001). The majority of urine samples precipitated envelope crystals of calcium oxalate dihydrate, while the remainder precipitated the monohydrate. A significantly (p less than 0.02) greater proportion of the urines from stone formers than from controls deposited calcium oxalate monohydrate, and this was attributed to a lower concentration of calcium in these urines. The minimum amounts of oxalate necessary to induce crystal nucleation did not differ between the two groups, but when the measured metastable limits were expressed as the product of the total (i.e. endogenous + that added to induce nucleation) concentrations of oxalate and calcium at which precipitation occurred, then these limits were significantly lower (p less than 0.05) in the stone formers than in the healthy subjects. However, when the metastable limits of a subgroup of stone formers and controls matched for 24-h urinary volume and calcium and urate concentrations were compared, no differences between the groups could be discerned.(ABSTRACT TRUNCATED AT 250 WORDS)

Calcium↗

The effect of crystalline monosodium urate on the crystallisation of calcium oxalate in whole human urine.

Samples of undiluted urine from normal men were preincubated with crystalline monosodium urate and their metastable limits and responses to a standard oxalate challenge were compared with results obtained from control samples preincubated without urate. Preincubation with urate had no significant effect on the metastable limits of the urines, the morphology, size, or growth rates of calcium oxalate crystals precipitated from the urines, or on the total amount of calcium oxalate deposited in a given time. It was concluded that particulate monosodium urate is unlikely to influence calcium oxalate stone formation by binding to and attenuating the potency of urinary inhibitors.

Calcium Oxalate↗

The effect of monosodium urate on the capacity of urine, chondroitin sulphate and heparin to inhibit calcium oxalate crystal growth and aggregation.

In order to investigate the possibility of interaction between urinary glycosaminoglycans and particulate monosodium urate, growth and aggregation rates of calcium oxalate seed crystals were measured in the presence of heparin, chondroitin sulphate and normal urine after preincubation with and without monosodium urate (0.5 mg./ml.). Rates of crystal aggregation in the presence of heparin and chondroitin sulphate were significantly (p less than 0.0005) increased after pretreatment with sodium urate, indicating a reduction in the inhibitory potency of heparin and chondroitin sulphate by this salt. A similar effect was observed with the rate of crystal growth in the presence of heparin (p less than 0.01). In contrast, the rate of growth in the presence of chondroitin sulphate was unaffected. Pretreatment with sodium urate had an inconsistent effect on the rate of crystal growth in the presence of 10 normal human urine samples, but significantly (p less than 0.001) raised the rate of crystal aggregation. It was concluded that the influence of urate on crystal aggregation in the presence of urine may be a result of its binding to endogenous chondroitin sulphate, but may not be of practical consequence in the pathogenesis of calcium oxalate renal stones.

Calcium Oxalate↗

A method for studying inhibitory activity in whole urine.

A method has been developed for inducing and quantifying calcium oxalate crystallisation in whole human urine. The propensity of a given urine to induce crystal formation was described in two ways: its ability to resist spontaneous nucleation of calcium oxalate crystals was assessed by titrating 20 mls of the urine with increasing quantities of sodium oxalate (0-150 mumol) to determine its practical metastable limit. This limit was inversely related to the endogenous calcium concentration; its capacity to inhibit crystal growth was quantified by determining the rate of growth of calcium oxalate crystals precipitated in response to a fixed oxalate load (30 mumol) above its metastable limit. The crystals produced were predominantly calcium oxalate dihydrate and were morphologically identical to those occurring naturally in urine. Citrate had no effect on the metastable limits of 3 urines examined, but markedly inhibited crystal growth. Pyrophosphate had a similar effect on crystal growth, and in addition, raised the metastable limit of one of the urine samples.

Calcium Oxalate↗

The effect of saline bladder washings on calcium oxalate crystal growth and aggregation.

Saline bladder washouts were obtained from 31 normal patients undergoing routine cystoscopy. A urine control was prepared by diluting a urine sample to the same creatinine concentration as the bladder washout. The inhibitory activities of the samples were then measured in a calcium oxalate seeded crystallization system. Washouts from the first 9 patients inhibited crystal aggregation more strongly than did the controls. This was attributable to microscopic blood contamination, since in the following 22 subjects, in whom contamination was excluded by the use of sensitive haemoglobin test strips, no increase in inhibition of aggregation was seen. The inhibition of calcium oxalate crystal growth by the washouts was consistently greater than that by the urine controls (p less than 0.05). This suggests that the bladder mucosa is a source of inhibitor(s) of crystal growth but not crystal aggregation.

Calcium Oxalate↗

The relationship between urinary inhibitory activity and endogenous concentrations of glycosaminoglycans and uric acid: comparison of urines from stone-formers and normal subjects.

The inhibitory effect of urine from 64 male stone-formers and from 42 normal men on the growth and aggregation of calcium oxalate crystals was measured. The degree of inhibition of each urine specimen was related to the endogenous concentrations of glycosaminoglycans, uric acid, and creatinine, and to the ratio of glycosaminoglycan to uric acid concentrations. No significant difference between the two groups of subjects with regard to the effect of urine on crystal growth or aggregation was found. Inhibitory activity was found to be significantly correlated with the urinary concentration of glycosaminoglycans, creatinine and uric acid, but not to the ratio of glycosaminoglycan/uric acid concentrations. It was concluded that urinary inhibitory activity depends only partly on the endogenous concentration of glycosaminoglycans and that the inhibitory activity of these compounds in vitro does not depend on the associated level of uric acid in the urine.

Adult↗

The evaluation of risk factors in male stone-formers attending a general hospital out-patient clinic.

The daily urinary excretion of calcium, oxalate, glycosaminoglycans and uric acid, and the 24-h urinary pH and volume were measured in 61 normal men and in 81 men with a history of renal stone disease. The following features of these data were noted: No significant difference could be demonstrated between the stone-formers and normals with respect to any of the variables measured. The values of each of the urinary parameters were positively and significantly correlated with those of at least two other parameters in one or both subject groups. The probability density histograms constructed from the data for each urinary variable in each subject group were unsuitable as the basis for calculation of individual relative risk factors. Thus it was concluded that the data were inappropriate for the calculation of "overall relative probability of forming stones" (P'SF) and that such an index is unlikely to be of use in the assessment and management of stone-formers attending a general hospital out-patient clinic.

Calcium↗

Factors affecting measurement of urinary oxalate.

Using a gas-chromatographic method, we examined the effects of phosphate concentration, added calcium chloride, and pH on precipitation of oxalate from urine. All three factors are important, but the pH of precipitation is particularly so, especially in the presence of even normal concentrations of ascorbic acid. At pH 8, increases in measured oxalate ranged from 20% at an ascorbic acid concentration of 1 mmol/L to more than 300% at 15 mmol/L. Ascorbic acid is rapidly converted to oxalate at alkaline pH. We also investigated the stability of both untreated and acidified urine containing ascorbic acid during storage for up to one month at -70, -20, and 4 degrees C, and room temperature. After one month, untreated collections were stable at -70 degrees C and acidified collections at -20 and -70 degrees C. We recommend conditions for assay and storage of urine specimens that are to be assayed for oxalate under which positive interference by ascorbic acid is minimized.

Ascorbic Acid↗